---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Efficacy and safety"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Efficacy and safety. Topics: Summary: development status, pharmacology, dose selection, and Himalayas-1 phase 3 design; Summary: ORIC-944-01 efficacy by cohort and data cutoff (company-reported); Summary: ORIC-944-01 safety by cohort and data cutoff (company-reported); Summary: other PRC2 and EZH2 inhibitors in mCRPC (cross-trial context). 4 evidence topics quoted from 29 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary/efficacy-and-safety"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Efficacy and safety

<a id="heading-1.1.2"></a>

## 1.1.2 Rinzimetostat Efficacy and Safety

<a id="topic-1.1.2-1"></a>

### Summary: development status, pharmacology, dose selection, and Himalayas-1 phase 3 design

- Rinzimetostat (ORIC-944) is an investigational oral allosteric inhibitor of polycomb repressive complex 2 (PRC2) that binds the embryonic ectoderm development (EED) subunit, which prevents methylation of histone 3 at lysine 27 and depletes H3K27 trimethylation (H3K27me3). ORIC Pharmaceuticals has “not submitted for, or obtained, regulatory approval for any product candidate”. ORIC filed and cleared an investigational new drug application with the FDA in the fourth quarter of 2021 and holds a worldwide, exclusive license from Mirati entered on August 3, 2020.
- In single-agent dosing, ORIC reported, as of December 10, 2023, an approximate 20-hour clinical half-life, no signs of cytochrome P450 autoinduction, and a maximal decrease (≥75%) in H3K27me3 in peripheral blood monocytes at doses as low as 200 mg once daily. ORIC reported that pharmacokinetic and pharmacodynamic data were “highly consistent as a single agent and in combination with darolutamide”, and that in the food-effect cohort “there does not appear to be a significant food effect”.
- After dose exploration, ORIC selected provisional doses of 400 mg and 600 mg once daily with darolutamide 600 mg twice daily, and 600 mg, 800 mg, and 1,200 mg once daily with apalutamide 240 mg once daily. In dose optimization, 18 participants received 400 mg and 15 received 600 mg once daily with darolutamide. ORIC’s exposure-response analysis across 113 participants (single-agent and combination) found no correlation between exposure and radiographic progression-free survival (rPFS), PSA reduction, ctDNA reduction, or H3K27me3 changes, and significant correlations with grade 2 or higher, grade 3 or higher, and serious adverse events, gastrointestinal and hematologic adverse events, and treatment modifications. ORIC selected 400 mg once daily with darolutamide as the recommended phase 3 dose (RP3D), in accordance with the FDA’s Project Optimus initiative. Rinzimetostat is taken orally once daily on a continuous schedule in 28-day cycles, and with or without food in Himalayas-1.
- Himalayas-1 (NCT07723248; protocol ORIC-944-05) is a randomized, open-label, global, multicenter phase 3 trial whose protocol ORIC finalized after End-of-Phase 1 interactions with the FDA and other health authorities. ORIC announced its initiation in July 2026; the registry lists an actual start of 2026-08-03, status “Recruiting”, estimated primary completion in 2028-03, and estimated study completion in 2030-09. ORIC sponsors the trial, and Bayer supplies darolutamide under an agreement dated July 7, 2026.
- Approximately 600 participants with mCRPC whose disease progressed on abiraterone given for ≥12 weeks in the mCSPC or first-line mCRPC setting, with ECOG performance status 0 or 1, are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily or to a prespecified physician’s choice of control: an androgen receptor pathway inhibitor (ARPI), with a second 1:1 randomization to darolutamide 600 mg twice daily or enzalutamide 160 mg once daily, or docetaxel 75 mg/m2 intravenously every 21 days for up to 10 cycles. Randomization is stratified by prior docetaxel in the mCSPC setting, control category (ARPI or docetaxel), and hepatic metastases. Prior ARPIs other than abiraterone and other prior systemic anticancer therapy are excluded, except docetaxel for mCSPC. The trial is planned across approximately 250 sites in 25 countries.
- The primary endpoint is rPFS by blinded independent central review (BICR), per RECIST 1.1 for soft tissue and PCWG3 for bone, or death. Overall survival is the key secondary endpoint and will be formally tested only if the primary rPFS analysis is statistically significant. Other secondary endpoints include objective response rate, duration of response, PSA50 and PSA90 response, time to PSA progression, time to first symptomatic skeletal event, adverse events, pharmacokinetics, and patient-reported outcomes (BPI-SF, FACT-P, EQ-5D-5L, and PRO-CTCAE). ORIC expects its cash runway to extend into the second half of 2028, beyond the anticipated primary endpoint readout.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm); [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421); [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [ORIC Pharmaceuticals second quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates/)

<a id="topic-1.1.2-2"></a>

### Summary: ORIC-944-01 efficacy by cohort and data cutoff (company-reported)

ORIC-944-01 (NCT05413421) is a first-in-human, open-label, multicenter phase 1/1b study of rinzimetostat as a single agent (Part I), in combination with an ARPI (Part II), and in combination dose optimization (Part III). ORIC reported all results below in press releases, investor presentations, and SEC filings; no Himalayas-1 results are available.

- Apalutamide combination dose escalation, 600 mg and 800 mg (December 10, 2024 cutoff; 6 participants): 3 of 6 participants achieved confirmed PSA50 responses, of whom 2 achieved confirmed PSA90 responses; all PSA responses were maintained for ≥12 weeks, including a confirmed PSA90 response ongoing at 38 weeks.
- Combination dose exploration, 400 mg to 800 mg with apalutamide or darolutamide (PSA data as of May 9, 2025; 17 participants with a median of three prior lines, including abiraterone): PSA50 response in 10 of 17 (59%), confirmed in 8 of 17 (47%), with one additional response pending confirmation; PSA90 response in 4 of 17 (24%), all confirmed. ORIC reported PSA responses at all dose levels and at comparable rates with each partner.
- Combination dose exploration, 400 mg to 1,200 mg with apalutamide or darolutamide (September 2025 cutoff; 20 participants, including the 17 reported in May 2025; 100% with prior abiraterone and 35% with prior docetaxel): PSA50 response in 11 of 20 (55%) unconfirmed and 8 of 20 (40%) confirmed; PSA90 response in 4 of 20 (20%), all confirmed. Among 17 participants with ctDNA samples and evidence of ctDNA at baseline, assessed at cycle 2 day 1, 13 (76%) had a ctDNA reduction greater than 50% and 10 (59%) changed from detected ctDNA (≥0.5%) to non-detected ctDNA (<0.5%); ctDNA remained detected in 5 of 17 (29%) and remained non-detected in 2 of 17 (12%).
- Darolutamide dose optimization, 400 mg, post-abiraterone cohort (18 participants treated; median two prior lines, 39% with prior docetaxel): as of March 6, 2026, in 18 efficacy-evaluable participants with a median follow-up of 4.9 months, landmark rPFS rates were 93% at 3 months, 84% at 4 months, and 84% at 5 months; ORIC lists median rPFS as “Not mature”. At the January 16, 2026 clinical cutoff, among 15 participants with at least one post-baseline PSA assessment, PSA50 response occurred in 7 of 15 (47%), confirmed in 5 of 15 (33%), and PSA90 response in 2 of 15 (13%), confirmed in 1 of 15 (7%). Among 14 participants with detectable ctDNA at baseline (data on file as of March 11, 2026), a 50% molecular response (MR50) occurred in 10 of 14 (71%) and a 90% molecular response (MR90) in 4 of 14 (29%), across AR-mutated, AR-amplified, and AR wildtype genotypes.
- Darolutamide dose optimization, 600 mg, post-abiraterone cohort (15 participants treated): no cohort-level efficacy figures are reported; ORIC stated that its exposure-response analysis showed that 400 mg and 600 mg once daily “provided comparable efficacy”.
- Post-androgen receptor inhibitor cohort, 400 mg with darolutamide (March 6, 2026 cutoff; 19 participants with mCRPC previously treated with AR inhibitors): landmark rPFS rates were 93% at 3 months, 85% at 4 months, and 85% at 5 months, with a median follow-up of 4.8 months.
- Food-effect cohort, 400 mg fed with darolutamide (March 6, 2026 cutoff): two confirmed PSA50 responses and one confirmed PSA90 response occurred in the first five participants dosed.

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421); [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/); [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/); [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-1.1.2-3"></a>

### Summary: ORIC-944-01 safety by cohort and data cutoff (company-reported)

- Single agent (December 10, 2023 cutoff): ORIC reported only grade 1 and 2 treatment-related adverse events (TRAEs) at dose levels corresponding with strong target engagement.
- Single-agent dose escalation, 100 mg to 900 mg (December 10, 2024 cutoff; 25 participants): TRAEs in ≥10% of participants were diarrhea in 10 (40%), fatigue in 8 (32%), decreased appetite in 8 (32%), nausea in 7 (28%), anemia in 5 (20%; grade 3 in 3 [12%]), platelet count decreased in 5 (20%; grade 3 in 2 [8%]), white blood cell count decreased in 3 (12%; grade 3 in 1 [4%]), and blood creatinine increased, dizziness, and vomiting in 3 (12%) each. At 900 mg (6 participants), grade 3 anemia and grade 3 platelet count decrease each occurred in 2 (33%). No grade 4 or 5 events were reported.
- Apalutamide combination dose escalation, 600 mg and 800 mg (December 10, 2024 cutoff; 6 participants): TRAEs were primarily grade 1 and 2, with one grade 3 TRAE of fatigue; the first two dose levels cleared without dose-limiting toxicities or treatment discontinuations related to safety.
- Combination dose exploration, 400 mg to 800 mg (April 22, 2025 cutoff; 17 participants): diarrhea, the most common TRAE, occurred in 9 of 17 (53%), with one grade 3 event; no grade 4 or 5 TRAEs were attributed to rinzimetostat with apalutamide or darolutamide.
- Combination dose exploration, 400 mg to 1,200 mg (September 2025 cutoff; 20 participants: 3 at 400 mg, 9 at 600 mg, 5 at 800 mg, 3 at 1,200 mg): treatment-emergent adverse events attributed to study treatment were diarrhea (grade 1 to 2 in 11 [55%] and grade 3 in 1 [5%]), fatigue in 9 (45%), nausea in 7 (35%), dysgeusia in 5 (25%), vomiting and hypothyroidism in 4 (20%) each, and constipation and blood creatinine increased in 3 (15%) each. No grade 4 or 5 events were attributed to study treatment. One participant discontinued for a TRAE of grade 1 diarrhea and grade 2 nausea.
- Darolutamide dose optimization, post-abiraterone cohorts (January 2026 cutoff): with 400 mg (18 participants), fatigue occurred in 7 (39%), diarrhea in 4 (22%), nausea in 4 (22%), blood creatinine increased in 3 (17%), and decreased appetite and anemia in 2 (11%) each; grade ≥3 TRAEs occurred in 6% (a single grade 3 TRAE), there were no serious TRAEs, and no grade 4 or 5 events were attributed to rinzimetostat or darolutamide. Dose interruptions occurred in 6%, dose reductions in none, and discontinuations in 6%. With 600 mg (15 participants), fatigue occurred in 6 (40%), diarrhea in 5 (33%), nausea in 4 (27%), blood creatinine increased and anemia in 2 (13%) each, and decreased appetite in 1 (7%); dose interruptions occurred in 13%, dose reductions in 7%, and discontinuations in 13%.
- Darolutamide dose optimization, post-ARPI safety set including the post-abiraterone participants (January 2026 cutoff; 72 participants): with 400 mg (37 participants), fatigue occurred in 10 (27%), diarrhea and nausea in 7 (19%) each, blood creatinine increased in 6 (16%; grade 3 in 1 [3%]), decreased appetite in 5 (14%), and anemia in 4 (11%), with “8% Grade 3”; dose interruptions occurred in 11%, reductions in 3%, and discontinuations in 3%. With 600 mg (35 participants), diarrhea occurred in 13 (37%), fatigue, nausea, and blood creatinine increased in 8 (23%) each, anemia in 6 (17%; grade 3 in 1 [3%]), and decreased appetite in 5 (14%), with “11% Grade 3”; dose interruptions occurred in 17%, reductions in 9%, and discontinuations in 11%. One grade 4 acute kidney injury was reported in this safety set.
- Food-effect cohort, 400 mg fed (March 6, 2026 cutoff; first five participants): all TRAEs were grade 1 except a single grade 2 TRAE.

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm); [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/); [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-1.1.2-4"></a>

### Summary: other PRC2 and EZH2 inhibitors in mCRPC (cross-trial context)

The trials below combined a PRC2 or EZH2 inhibitor with enzalutamide or abiraterone and enrolled populations with follow-up durations that differ from those of ORIC-944-01; every comparison with rinzimetostat is cross-trial.

- Mevrometostat plus enzalutamide, randomized phase 1 dose expansion after abiraterone (September 2, 2024 cutoff; 81 participants; mevrometostat 1250 mg twice daily fasted plus enzalutamide, n=41, or enzalutamide, n=40; median follow-up 9.6 months): median rPFS was 14.3 months with the combination and 6.2 months with enzalutamide (hazard ratio 0.51; 90% CI 0.28 to 0.95), and confirmed PSA50 response occurred in 34.1% and 15.4%. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 53.7% and 42.5%, and diarrhea in 78.0% with the combination; there were no treatment-related deaths.
- Mevrometostat 875 mg twice daily with food plus enzalutamide: as of November 15, 2024, among 29 participants, serious mevrometostat-related TEAEs occurred in 3 (10.3%), all grade 3, and TEAEs led to withdrawal of mevrometostat in 4 (13.8%); this dose was selected for phase 3. As of September 1, 2025, in cohort 2C (14 participants with prior abiraterone, enzalutamide naive), median rPFS was not estimable (90% CI 6.2 to not estimable) and confirmed PSA50 response occurred in 6 (42.9%); in cohorts 2A and 2C combined, grade ≥3 TEAEs occurred in 41.3% and grade ≥3 mevrometostat-related TEAEs in 31.0%.
- Mevrometostat phase 3: MEVPRO-1 (NCT06551324) is an open-label trial of mevrometostat plus enzalutamide versus physician’s choice of enzalutamide or docetaxel after ≥12 weeks of abiraterone, stratified by prior docetaxel in mCSPC, physician’s choice of comparator, and hepatic metastases, with rPFS by BICR as the primary endpoint and overall survival as a key secondary endpoint; its registry status is “Active, not recruiting”, with a listed date of 2027-02-28. MEVPRO-2 (NCT06629779) enrolls treatment-naive mCRPC, and MEVPRO-3 (NCT07028853) enrolls ARPI-naive mCSPC.
- Tazemetostat plus enzalutamide, CELLO-1 randomized phase 2 after abiraterone (41 and 40 participants analyzed): median rPFS was 22.1 months (95% CI 16.6 to 27.6) with the combination and 11.1 months (95% CI 5.7 to 16.5) with enzalutamide, and confirmed PSA50 response occurred in 19.5% and 15.0%. The study was terminated early when the sponsor discontinued tazemetostat development in mCRPC, and the primary endpoint was not met. Tazverik (tazemetostat) was voluntarily withdrawn from the U.S. market because of an increased rate of hematologic second primary malignancies: as of March 6, 2026, 18 of 318 (5.7%) participants treated with tazemetostat in a study developed them, compared with no reported events in the control arm.
- Class safety: a 2026 review states that no comparable secondary-malignancy signal has been publicly reported for mevrometostat, valemetostat, or tulmimetostat, calling this “reassuring but not yet definitive”, and notes that the median follow-up of approximately 9.6 months in the phase 1/2 mevrometostat experience is shorter than the interval over which therapy-related MDS/AML typically emerge. ORIC reported that no hematologic tumorigenesis was observed in a 13-week rat GLP toxicology study of rinzimetostat, in contrast to tazemetostat.
- CPI-1205 plus enzalutamide (ProSTAR phase 1b/2): composite response rate was 31.4% with the combination and 17.1% with enzalutamide, and best objective response rate 7.89% and 5.71%. ORIC lists CPI-1205 and tazemetostat as “Discontinued” and mevrometostat as in ongoing phase 3 trials.
- ORIC benchmark comparison (March 2026 presentation): ORIC set rinzimetostat 400 mg plus darolutamide (n=18; median follow-up 4.9 months; landmark rPFS 93%, 84%, and 84% at 3, 4, and 5 months; grade ≥3 treatment-related adverse events [TRAEs] 6%; no serious TRAEs) beside mevrometostat 875 mg fed plus enzalutamide (n=14; 9.2 months; 92%, 92%, and 84%; grade ≥3 TRAEs 36%; serious TRAEs 21%), mevrometostat 1250 mg fasted plus enzalutamide (n=41; 11.7 months; 92%, 86%, and 80%; 49%; 24%), and enzalutamide (n=40; 9.0 months; 78%, 70%, and 60%; grade ≥3 TRAEs 23%). Dose reductions were none, 7%, and 37%, and discontinuations 6%, 7%, and 2%, for rinzimetostat, mevrometostat fed, and mevrometostat fasted. ORIC states that competitor rPFS percentages were “estimated from published data” and labels the table a “Cross-trial comparison in previously treated mCRPC patients”.

Source: [Schweizer et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.LBA138); [Matsubara et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5046); [Matsubara et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.195); [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/); [ClinicalTrials.gov NCT06551324](https://clinicaltrials.gov/study/NCT06551324); [ClinicalTrials.gov NCT07028853](https://clinicaltrials.gov/study/NCT07028853); [ClinicalTrials.gov NCT04179864](https://clinicaltrials.gov/study/NCT04179864); [ClinicalTrials.gov NCT04179864 results](https://clinicaltrials.gov/study/NCT04179864?tab=results); [FDA Tazverik safety alert (2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik); [Alumkal and Ellis (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13552191/); [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/); [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf); [ClinicalTrials.gov NCT03480646 results](https://clinicaltrials.gov/study/NCT03480646?tab=results); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
